Israeli Industry And Investment Leaders Discuss Market Development
Ruti Alon, CEO of venture capital fund Medstrada and co-chair of the MIXiii-BIOMED conference noted that as the sector has matured, there are indeed a number of biopharma companies developing drugs in clinical and even late stages in a variety of areas, citing the likes of UroGen Pharma, VBL Therapeutics, Anchiano Therapeutics, Pluristem and BioLineRx. Their advancement is due in part to “the Nasdaq opening its doors to Israeli biotechs and the financial boost that the life science ecosystem received with the addition of new VCs in the healthcare space,” with aMoon and the IBF joining firms such as OrbiMed, Pontifax, Arkin Bio Ventures and Clal Biotechnology Industries.
“I believe that this positive momentum can eventually create a sustainable and leading life science industry in Israel,” Alon concluded.
Naschitz and Sidransky will be co-chairing, respectively, the AI/Digital Health and TransformativeCancer Therapies tracks at MIXiii-BIOMED, Israel’s leading international life science conference and exhibition, taking place on May 14-16 in Tel Aviv.